Inotiv Advances NAM #
Inotiv, Inc. has announced a strategic initiative to leverage LifeNet Health’s proprietary TruVivo® platform within its Discovery and Translational Sciences business. This collaboration aims to advance New Approach Methodologies (NAM) by improving human-relevant science and translational predictivity in drug discovery. The TruVivo® platform uses primary human hepatocytes cultured with human-derived feeder cells to create physiologically relevant in vitro models.
Key Highlights #
- The TruVivo® platform uses primary human hepatocytes cultured with human-derived feeder cells to create physiologically relevant in vitro models.
- The initiative focuses on aligning preclinical models with human biology to accelerate therapy development.
- The platform’s versatility allows for the expansion of human-relevant tissue models beyond the liver, supporting innovation for a wide range of diseases.
Statements #
Translational science is about connecting basic research to patient outcomes. Integrating the TruVivo® platform into our disease pharmacology offering allows us to better align preclinical models with human biology.
— Scott Daniels, PhD, Senior Vice President of Discovery & Translational Sciences at Inotiv
Our mission is to save lives, restore health, and give hope by accelerating scientific innovation that translates into meaningful human impact. This collaboration underscores our shared vision of transforming preclinical research through human-relevant technologies.
— Susan Campbell, General Manager LifeSciences at LifeNet Health
About the Organizations #
Inotiv, Inc. is a leading Contract Research Organization (CRO) specializing in nonclinical and analytical drug discovery and development services. LifeNet Health LifeSciences delivers human-based research solutions that accelerate discovery and improve patient safety.
Learn More #
Read the full press release at LifeNet Health LifeSciences Inotiv’s Official Announcement